Medtronic has announced the European launch of a new peripheral angioplasty balloon, TOTAL across that targets challenging lesions in the lower-extremity, including below-the-knee arteries associated with critical limb ischaemia.
The most recent ZILVER PTX trial data, presented at the Controversies and Updates in Vascular Surgery (CACVS) congress (23–25 January 2014, Paris, France), demonstrate sustained positive results for the paclitaxel-eluting stent (Cook Medical) vs. bare metal stent in patients with peripheral arterial disease.
Study presenter Michael Werk (Department of Radiology of the Martin-Luteher-Hospital, Hubertus-Hospital, Berlin, Germany) reported that the PACIFIER study was a proof-of-concept trial that was designed to demonstrate the efficacy of In.Pact Pacific drug-coated balloon in reducing restenosis of femoropopliteal stenosis and occlusions compared with standard percutaneous transluminal angioplasty (PTA; uncoated balloons). He added that it was an investigator initiated, multicentre study in which patients were randomised in a one-to-one fashion to receive the In.Pact Pacific balloon (41 patients; 44 lesions) or standard PTA (44 patients; 47 lesions), commenting: “The primary endpoint was six-month late lumen loss.”
A clinical study has demonstrated the feasibility of the Esprit drug-eluting bioresorbable vascular scaffold (Abbott), with no deaths or amputations, in patients with symptomatic atherosclerotic disease of the superficial femoral artery or iliac arteries.
A screening programme for abdominal aortic aneurysms (AAA), integrated into an electronic health record, dramatically reduced the number of unscreened at-risk men by more than 50% within 15 months, according to a Kaiser Permanente study published in the Journal of Vascular Surgery.
Two-year follow-up data have shown that BioMimics 3D, a nitinol stent with unique three-dimensional helical geometry, developed by Veryan Medical, provides an improvement in long-term patency compared to a straight nitinol control stent in patients undergoing femoropopliteal artery intervention for symptomatic peripheral arterial disease.
Interim results from the Chocolate balloon angioplasty registry conducted in the USA demonstrate that use of the TriReme Medical Chocolate percutaneous transluminal angioplasty balloon achieved high rates of treatment success and limb preservation in patients with peripheral arterial disease.
One year results from the prospective, multicentre, randomised, core lab-adjudicated FAIR trial comparing drug-eluting balloon to standard percutaneous transluminal angioplasty for the treatment of superficial femoral artery in-stent restenosis showed positive outcomes for the drug-eluting balloon.
Endologix has announced the US launch of its new Vela proximal endograft system, a clinical solution for endovascular repair in a broad range of aortic neck anatomies. A press release from the company says the Vela system is specifically designed for the treatment of proximal aortic neck anatomies during an endovascular aneurysm repair procedure using the Endologix AFX endovascular AAA System.
InspireMD has announced that its new CGuard carotid embolic protection system has been successfully implanted in recent procedures, including a patient treated during the 17(th) Annual Symposium on Interventional Cardiology & Angiology held in Hamburg, Germany on 1 February 2014.
Interventional News has learned that the UK CAVA trial, a four-way randomised controlled trial of long-term venous access devices for the delivery of chemotherapy (Ports versus tunnelled central lines versus peripherally inserted central catheters) has begun.
Boston Scientific has announced the US launch and first use of the OffRoad re-entry catheter system. The system provides a new option to treat chronic total occlusions in the femoropopliteal arteries.
Biotronik has announced the release of its Passeo-18 Lux drug-eluting balloon in all countries accepting the CE mark, following recent CE approval. The Passeo-18 Lux DRB catheter has shown clinical efficacy in the BIOLUX P-I study. Data collected at six- and 12-month intervals demonstrated that patients treated with Passeo-18 Lux were less likely to require treatment again.
Six-month results from the prospective, single-arm, multicentre, European ESPRIT I trial being presented at the 26th annual International Symposium on Endovascular Therapy (ISET, 18–22 January, Miami, USA) suggest that the Esprit drug-eluting bioresorbable vascular scaffold (Abbott Vascular) appears to be effective in treating iliac and femoral lesions.
The most recent results of the multicentre, non-randomised, single-arm prospective STROLL trial were presented at the 26th annual International Symposium on Endovascular Therapy (ISET, 18–22 January, Miami, USA). The trial is studying the safety and efficacy of the S.M.A.R.T. stent (Cordis) in patients with obstructive superficial femoral artery disease.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos